SEARCH:   Advanced

Blood, 22 January 2009, Vol. 113, No. 4, pp. 793-796. Prepublished online as a Blood First Edition Paper on October 17, 2008; DOI 10.1182/blood-2008-07-172080. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-07-172080v1 113/4/793    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dhodapkar, M. V. Articles by Barlogie, B. Search for Related Content PubMed PubMed Citation Articles by Dhodapkar, M. V. Articles by Barlogie, B. Related Collections Free Research Articles Lymphoid Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003 Madhav V. Dhodapkar1, Antje Hoering2, Morie A. Gertz3, Saul Rivkin4, Jackie Szymonifka2, John Crowley2, and Bart Barlogie5 1 Section of Hematology and Yale Cancer Center, Yale University, New Haven, CT; 2 Cancer Research and Biostatistics, Seattle, WA; 3 Mayo Clinic (Eastern Cooperative Oncology Group), Rochester, MN; 4 Puget Sound Oncology Consortium, Seattle, WA; and 5 Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock The survival of patients with Waldenstrom macroglobulinemia (WM) varies enormously. The development of prognostic models in WM has been fraught by limited follow-up in current studies. Here, we update the outcome of a prospective WM trial with a median follow-up of 10 years for live patients. Of the 59 previously untreated patients who initially were observed, only 12 patients (21%) required therapy at a median follow-up of 100 months. Multivariate analysis among the 183 patients requiring therapy reaffirmed age 70 years or greater, previous nonprotocol therapy, and β-2 microglobulin (B2M) of 3 mg/dL or greater as prognostic factors. Importantly, increased serum lactate dehydrogenase (LDH) was identified as an additional independent variable, which improved risk assessment beyond the recent WM international prognostic scoring system (ISSWM). By using age, previous therapy, B2M, and LDH, we identified 3 risk groups with 8-year survival estimates of 55%, 33%, and 5% (P < .001). These data provide novel insights into factors predicting long-term outcome in WM. This trial has been registered with www.cancer.gov under ID 4852904. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. P. Treon How I treat Waldenstrom macroglobulinemia Blood, September 17, 2009; 114(12): 2375 - 2385. [Abstract] [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020